Intraperitoneal therapy with paclitaxel and cisplatin does not result in longer progression-free or overall survival in the adjuvant setting among patients with stage III ovarian cancer as compared with dose-dense paclitaxel and carboplatin, results of a study have shown. In addition, tolerability appears to have decreased with intraperitoneal therapy.
In the treatment of cytokine storm syndrome due to the coronavirus disease (COVID-19), administering tocilizumab via the intravenous (IV) route appears to be more effective than subcutaneous (SC) therapy, leading to earlier symptom improvement and better survival, according to a study.
Use of rivaroxaban, with or without aspirin, falls short of reducing the number of incident covert infarcts compared with aspirin alone in patients with stable coronary and peripheral vascular disease, according to a study.
Use of methimazole appears to elevate the risk of acute pancreatitis (AP), a recent study has found. This supports the warning issued by the European Medicine Agency (EMA) regarding a potential increased risk of AP in users of methimazole.
Use of eslicarbazepine acetate over the long term in the treatment of patients with focal epilepsy appears to be well tolerated and induces freedom from seizures, according to the results of an open-label study.
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).